Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1158/2159-8290.cd-18-0474 | Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids |
| https://doi.org/10.1158/2159-8290.cd-18-0715 | BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma |
| https://doi.org/10.1016/j.ygyno.2016.05.022 | Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline |
| https://doi.org/10.1006/gyno.1996.0065 | Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III Disease |
| https://doi.org/10.1158/1078-0432.ccr-17-1327 | Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study |
| https://doi.org/10.1158/1078-0432.ccr-20-0056 | Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study |
| https://doi.org/10.1016/s1470-2045(20)30061-9 | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial |
| https://doi.org/10.1016/j.jacr.2018.03.015 | ACR Appropriateness Criteria ® Staging and Follow-Up of Ovarian Cancer |
| https://doi.org/10.1200/jco.21.02016 | Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis |
| https://doi.org/10.1200/jco.21.02011 | Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial |
| https://doi.org/10.1200/jco.22.01207 | Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study |
| https://doi.org/10.1016/j.ygyno.2022.08.021 | Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma |
| https://doi.org/10.1016/j.jacr.2020.09.001 | ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Endometrial Cancer |
| https://doi.org/10.1158/0008-5472.can-23-3239 | R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts |
| https://doi.org/10.1016/j.jpainsymman.2024.01.010 | Discriminatory Healthcare Experiences and Medical Mistrust in Patients With Serious Illness |
| https://doi.org/10.1006/gyno.1998.4956 | Uterine Papillary Serous Carcinoma: Evaluation of Long-Term Survival in Surgically Staged Patients |
| https://doi.org/10.1097/aog.0b013e31819fe844 | Factors Affecting Risk of Mortality in Women With Vaginal Cancer |
| https://doi.org/10.1016/j.jacr.2013.07.017 | ACR Appropriateness Criteria Staging and Follow-up of Ovarian Cancer |
| https://doi.org/10.1097/lgt.0000000000000287 | Loop Electrosurgical Excision Procedure Instead of Cold-Knife Conization for Cervical Intraepithelial Neoplasia in Women With Unsatisfactory Colposcopic Examinations: A Systematic Review and Meta-Analysis |
| https://doi.org/10.1016/j.jacr.2019.02.011 | ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass, No Acute Symptoms |
| https://doi.org/10.1158/0008-5472.can-19-1991 | Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer |
| https://doi.org/10.1016/0090-8258(87)90297-6 | Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract |
| https://doi.org/10.1097/aog.0000000000003086 | Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma |
| https://doi.org/10.1016/j.jmig.2018.01.010 | Robotic, Laparoscopic, or Open Hysterectomy: Surgical Outcomes by Approach in Endometrial Cancer |
| https://doi.org/10.1097/aog.0000000000002677 | Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma |
| https://doi.org/10.1097/igc.0000000000000893 | Gynecologic Oncologist Views Influencing Referral to Outpatient Specialty Palliative Care |
| https://doi.org/10.1097/01.ogx.0000508241.20157.7e | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline |
| https://doi.org/10.1016/j.ygyno.2021.08.030 | Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer |
| https://doi.org/10.1158/1055-9965.epi-18-1194 | Use of Statin Medications Following Diagnosis in Relation to Survival among Women with Ovarian Cancer |
| https://doi.org/10.1016/j.ygyno.2020.05.023 | Promoting health equity in the era of COVID-19 |
| https://doi.org/10.1016/s1470-2045(14)70075-0 | SGO not soft on morcellation: risks and benefits must be weighed |
| https://doi.org/10.1002/cam4.1141 | Racial disparities in the utilization of preventive health services among older women with early‐stage endometrial cancer enrolled in Medicare |
| https://doi.org/10.1016/j.jacr.2020.01.031 | ACR Appropriateness Criteria® Placenta Accreta Spectrum Disorder |
| https://doi.org/10.1136/ijgc-2020-002240 | Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3 |
| https://doi.org/10.1016/j.ygyno.2021.03.015 | Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2 |
| https://doi.org/10.1016/j.gore.2021.100893 | Benign metastasizing leiomyoma, a rare imposter of metastatic cervical cancer |
| https://doi.org/10.1006/gyno.1996.4520 | Serum Inhibin and Disease Status in Women with Ovarian Granulosa Cell Tumors |
| https://doi.org/10.1016/j.mri.2012.06.002 | Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials |
| https://doi.org/10.1136/ijgc-2021-002803 | Impact of SARS-CoV-2 on training and mental well-being of surgical gynecological oncology trainees |
| https://doi.org/10.1016/j.ygyno.2021.08.002 | PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine |
| https://doi.org/10.1006/gyno.1997.4842 | A Retrospective Review of Paclitaxel-Associated Gastrointestinal Necrosis in Patients with Epithelial Ovarian Cancer |
| https://doi.org/10.1016/j.ygyno.2018.02.010 | Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP) |
| https://doi.org/10.1016/j.gynor.2012.12.007 | Painful clitoromegaly caused by rare epithelioid hemangioma |
| https://doi.org/10.1200/po.22.00355 | State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report |
| https://doi.org/10.1016/j.ygyno.2024.06.002 | A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma |
| https://doi.org/10.1016/0090-8258(89)90075-9 | Postoperative pain management in gynecologic oncology patients utilizing epidural opiate analgesia and patient-controlled analgesia |
| https://doi.org/10.1016/j.jacr.2019.05.015 | ACR Appropriateness Criteria® Gestational Trophoblastic Disease |
| https://doi.org/10.1016/j.ygyno.2013.04.006 | Ovarian cancer national alliance: A report of the 2012 Consensus Conference on Current Challenges in ovarian cancer |
| https://doi.org/10.1136/ijgc-2019-000567 | Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey |
| https://doi.org/10.1002/cam4.4260 | Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety |
| https://doi.org/10.1016/j.ygyno.2018.01.021 | Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things |
| https://doi.org/10.1016/j.ygyno.2018.02.011 | Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model |
| https://doi.org/10.1016/j.jacr.2021.08.011 | ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer |
| https://doi.org/10.1016/j.gim.2024.101307 | Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study |
| https://doi.org/10.1016/j.ygyno.2019.12.036 | Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models |
| https://doi.org/10.1016/j.ygyno.2020.06.501 | 51st Annual Meeting of the Society of Gynecologic Oncology |
| https://doi.org/10.1016/j.ygyno.2021.04.022 | Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care |
| https://doi.org/10.1007/978-3-030-16245-0_23 | Approach and Management of Cervical Cancer |
| https://doi.org/10.1016/j.ijgc.2024.100243 | Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up |
| https://doi.org/10.1016/0090-8258(87)90217-4 | Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: Prognostic implications of tumor persistence |
| https://doi.org/10.1006/gyno.2002.6584 | A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study |
| The gynecologist's perspective of liability and quality issues with the Papanicolaou smear. | |
| https://doi.org/10.1006/gyno.1999.5571 | Pretreatment Scalene Node Biopsy in Gynecologic Malignancy: Prudent or Passé? |
| https://doi.org/10.1007/b14187_7 | Pelvic Exenteration for Recurrent Pelvic Cancer |
| https://doi.org/10.1016/j.ygyno.2013.07.032 | Germline mutations in dna repair genes in women with ovarian, peritoneal, or fallopian tube cancer treated on GOG protocol 218 |
| https://doi.org/10.1016/j.ygyno.2014.07.011 | Germline mutations in cancer susceptibility genes in brca1 and brca2 negative families with ovarian and breast cancer |
| https://doi.org/10.1093/annonc/mdy285.208 | A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer |
| https://doi.org/10.1097/aog.0000000000003443 | Personal Reflections on Gynecologic Oncology and Its Future |
| https://doi.org/10.1136/ijgc-2019-esgo.29 | Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age |
| https://doi.org/10.1007/978-1-4471-4605-6_9 | Ovarian Cancer: Symptoms and Presentation |
| Does PERCIST normalized for body surface area, body weight, or ideal body weight equal PERCIST normalized for lean body mass? | |
| https://doi.org/10.1016/j.ygyno.2017.03.294 | Mutation profiling of uterine lavage fluid detects early-stage endometrial cancers and discovers a prevalent landscape of driver mutations in women without cancer |
| https://doi.org/10.1101/gr.279158.124 | Long-read DNA and cDNA sequencing identify cancer-predisposing deep intronic variation in tumor-suppressor genes |
| https://doi.org/10.1101/mcs.a006083 | Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation |
| https://doi.org/10.1101/mcs.a005652 | Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities |
| https://doi.org/10.1097/00002820-198112000-00005 | Sexuality and gynecologic cancer |
| https://doi.org/10.1101/2020.07.09.196378 | Molecular analysis of binding region of an ACE2 as a receptor for SARS-CoV-2 between humans and mammals |
| https://doi.org/10.1016/j.ygyno.2009.02.016 | SGO's 40th Annual Meeting on Women's Cancer, February 2009 |
| https://doi.org/10.1097/00006254-198410000-00019 | Adjuvant Postoperative Pelvic Radiation for Carcinoma of the Uterine Cervix |
| https://doi.org/10.1158/1557-3265.ovcasymp14-poster-ctrl-1206 | Abstract POSTER-CTRL-1206: The mutational landscape of fallopian tube carcinoma |
| https://doi.org/10.1002/cncr.22750 | Author reply |
| https://doi.org/10.1136/ijgc-2019-esgo.28 | Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3 |
| https://doi.org/10.1016/j.ygyno.2019.11.067 | The feasibility of screening for malnutrition in the outpatient setting and the prevalence of malnutrition in patients with primary ovarian cancer: a QI project |
| https://doi.org/10.1158/1557-3265.ovcasymp18-ap22 | Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER |
| https://doi.org/10.1016/j.ygyno.2019.04.030 | The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training |
| https://doi.org/10.6004/jnccn.2018.0059 | NCCN NewsNCCN Announces New Chief Medical OfficerNCCN Begins Work on Guidelines to Improve Cancer Care in the CaribbeanNew Tool Helps People with Leukemia Better Understand Their Treatment OptionsNew Translations of NCCN Guidelines for Patients Advance Global Mission to Empower People with Cancer |
| https://doi.org/10.1097/aog.0000000000001072 | In Reply |
| https://doi.org/10.1007/978-3-642-27841-9_6972-2 | Ovarian Cancer Chemotherapy |
| https://doi.org/10.1007/978-3-642-16483-5_6972 | Ovarian Cancer Chemotherapy |
| https://doi.org/10.1007/978-3-662-46875-3_6972 | Ovarian Cancer Chemotherapy |
| https://doi.org/10.1158/0008-5472.c.6511902.v1 | Data from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer |
| https://doi.org/10.1158/0008-5472.c.6511902 | Data from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer |
| https://doi.org/10.3410/f.740533807.793598344 | Faculty Opinions recommendation of The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. |
| https://doi.org/10.1136/ijgc-2023-igcs.7 | PO007LBA/#1550 Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study |
| https://doi.org/10.1101/2025.03.03.25323026 | HRDetect in Ovarian Carcinoma: Stratification and Therapeutic Implications |
| https://doi.org/10.1097/qad.0000000000004187 | Vaginal microbiome composition in women with HIV undergoing treatment of cervical transformation zone in a screen and treat program in Zambia |
| https://doi.org/10.1016/j.jand.2025.08.009 | Integrating Registered Dietitian Nutritionists’ Medical Nutrition Therapy Benefit Into Existing State Medicaid Coverage and Reimbursement Policy: Results From a Nationwide Medicaid Medical Nutrition Therapy Mapping Project |
| https://doi.org/10.1016/j.ygyno.2025.04.106 | An objective evaluation of “This is Our Lane”: A Society of Gynecologic Oncology Diversity, Inclusion and Health Equity Blog |
| https://doi.org/10.1080/07347332.2025.2588632 | Psychological flexibility, distress, and coping in ovarian cancer survivors |
| Treatment response in advanced ovarian cancer (AOC): Evaluation of tumor metabolism, CA-125, and RECIST criteria |